Current Research Funded by Kidneeds
Claire Harris (United Kingdom)
Dr Harris is analyzing a large cohort of patients with DDD to correlate the disease phenotype with specific assays for C3 nephritic factors. This research should provide a wealth of information on the functional characteristics of C3 nephritic factors and their impact on disease. The data analysis in this proposal will be refined to key assays – those proven to be most sensitive and most informative with respect to revealing novel characteristics of C3 nephritic factor-stabilized enzymes.
Wenchao Song (United States)
Dr Song will use a new animal model, the fHmut/mut.fP-/- mouse, to study DDD. These animals have uncontrolled activation of the alternative pathway (AP) of complement and glomerular C3 deposition. Properdin is known to initiate AP activation on certain surfaces and to prolong the half-life of C3 convertase. Its deficiency in the fHmut/mut.fP-/- mouse decreases the likelihood of activation of complement on any surfaces and exacerbates the renal pathology in these animals to produce a histological picture of DDD.
Joshua Thurman (United States)
The major goal of Dr Thurman's research is to develop an MR-based method to follow the deposition of C3d on the glomerular basement membrane in persons with DDD. Dr Thurman hopes to achieve this goal by using a chimeric protein that contains the C3d binding portion of CR2 linked to the Fc region of mouse IgG. This construct is conjugated to superparamagnetic iron oxide (SPIO) nanoparticles. SPIO negatively enhance and so on T2-weighted MRI images, the CR2-Fc conjugated SPIO particles darkened the image to permit detection of C3d, to which they bind. If successful, this technique would provide clinicians with a method of following disease at the glomerular level.
Home / Kidneeds Research